Skye Bioscience Shares Plunge as Investor Lawsuit Filed

Skye Bioscience’s stock is experiencing another significant downturn this week as the biotechnology firm faces a new class-action lawsuit. The legal action, filed on Tuesday, alleges that investors were misled regarding the efficacy of the company’s flagship drug candidate, Nimacimab. This development compounds existing pressure on the stock, which had already suffered a 60% collapse in October following disappointing clinical trial results.

Clinical Trial Setback Triggers Legal Challenge

The lawsuit centers on disappointing outcomes from the CBeyond™ Phase 2a clinical trial, whose results were disclosed on October 6. Nimacimab failed to achieve its primary endpoint for weight reduction when administered as a standalone treatment compared to placebo. More concerningly, preliminary analyses indicated lower-than-anticipated drug concentration levels, suggesting potentially insufficient dosing. Market reaction was immediate and severe, with shares plummeting by $2.85 to close at $1.90.

Despite these challenges, combination therapy data offered a glimmer of hope. When Nimacimab was administered alongside Semaglutide, researchers observed significantly improved outcomes:
* Weight reduction proved 29% more effective than Semaglutide alone
* Patients experienced an additional 3.2 cm reduction in waist circumference
* Significantly less weight regain after treatment cessation (18.1% versus 49.8%)

Should investors sell immediately? Or is it worth buying Skye Bioscience?

Financial Position Deteriorates

Recent quarterly figures released November 10 further illustrate the company’s challenging position. Skye Bioscience reported a third-quarter 2025 net loss of $12.8 million, substantially higher than the $3.9 million loss recorded during the same period last year. Research and development expenses surged to $9.4 million, driven primarily by increased clinical trial and contract manufacturing costs. The company maintains that its $35.3 million in liquid assets provides sufficient funding through 2027.

Strategic Pivot Underway

The critical question for investors is whether Skye Bioscience can successfully navigate this crisis. Management has already initiated a strategic shift, prioritizing combination therapy development while continuing to explore higher-dose monotherapy regimens. Market attention now focuses on data from the 26-week extension study expected in the first quarter of 2026, which will inform planning for subsequent Phase 2b trials.

From a technical perspective, the stock continues to demonstrate pronounced weakness. Since the quarterly earnings release, shares have drifted downward to approximately $1.30, hovering near the 52-week low of $1.14. The June 2025 all-time high of $5.75 appears increasingly distant. With the dual overhang of litigation risk and clinical uncertainty, Skye Bioscience represents a high-risk investment proposition in the current biotech landscape.